The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
April 9, 2025
View Complete Issue         Table of Contents 2019 
Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair
April 9, 2025 (Issue: 5104)
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by the FDA for same indications as Xolair (see Table 1). Omlyclo is the first Xolair biosimilar...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair
Article code: 5104a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.